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PGAP6, also known as TMEM8A, is a phospholipase A2 with
specificity to glycosylphosphatidylinositol (GPI) and expressed
on the surface of various cells. CRIPTO, a GPI-anchored co-re-
ceptor for a morphogenic factor Nodal, is a sensitive substrate
of PGAP6. PGAP6-mediated shedding of CRIPTO plays a criti-
cal role in an early stage of embryogenesis. In contrast, CRYP-
TIC, a close family member of CRIPTO, is resistant to PGAP6.
In this report, chimeras between CRIPTO and CRYPTIC and
truncate mutants of PGAP6 were used to demonstrate that the
Cripto-1/FRL1/Cryptic domain of CRIPTO is recognized by an
N-terminal domain of PGAP6 for processing. We also report
that among 56 human GPI-anchored proteins tested, only gly-
pican 3, prostasin, SPACA4, and contactin-1, in addition to
CRIPTO, are sensitive to PGAP6, indicating that PGAP6 has a
narrow specificity toward various GPI-anchored proteins.
Glycosylphosphatidylinositol (GPI)–anchored proteins
(GPI-APs) are tethered to the outer leaflet of plasmamembrane
by a covalently linked glycolipid (1). Some GPI-APs are released
from the cell surface after cleavage of the GPI anchor by GPI-
specific hydrolytic enzymes (GPIases). There are several combi-
nations of a select GPI-AP and a cognate GPIase with particular
biological significance, such as testis-specific angiotensin-con-
verting enzyme (tACE) cleaving the GPI anchors of TEX101
and LY6K in sperm (2, 3) by its putative endomannosidase activ-
ity (4). Shedding of these GPI-APs from sperm is critical for
sperm maturation (3). Several members of the glycerophospho-
diesterase (GDE) family are GPI-specific phospholipase C or
D (PLC or PLD). GDE2 is involved in the shedding of RECK
(reversion-inducing cysteine-rich protein with Kazal motifs), a
GPI-anchored protease inhibitor, from certain neuronal cells,
and the process is critical for neuronal differentiation (5). GDE2
is also involved in neuroblastoma differentiation through release
of glypican 6 (GPC6) (6). GDE3 regulates cell adhesion, migra-
tion, and invasion by shedding uPAR, a GPI-anchored urokinase
plasminogen activator receptor (7). GDE3 releases another GPI-
AP, CNTFRa, from oligodendrocyte precursors and regulates
their proliferation (8).
PGAP6, also known as TMEM8A, is a cell-surface phospholi-
pase A2 (PLA2) with specificity toward GPI (9) and is widely
expressed (RRID:SCR_006710) (10). PGAP6 has a large extrac-
ellular portion in the N-terminal part and seven transmem-
brane (TM) domains in the C-terminal part. PGAP6 belongs to
a superfamily, termed CREST for alkaline ceramidase, PAQR
receptor, Per1, SID-1, and TMEM8 (11). The CREST super-
family includes several lipases that have conserved, presumably
catalytic amino acids within the TM domains. We reported
that CRIPTO, a GPI-AP (12), is a sensitive substrate of PGAP6
(9). CRIPTO plays a role in early embryonic development by
acting as a co-receptor for a morphogenic factor Nodal (13, 14).
PGAP6-dependent shedding of CRIPTO is critical for its role
(9), especially for the generation of the anterior–posterior axis
(15).
Mechanistically, PGAP6 acts on CRIPTO in the plasma
membrane and removes one fatty acyl-chain from the GPI
anchor, generating CRIPTO bearing only one fatty acyl-chain.
CRIPTO that is anchored to the plasma membrane by a single
fatty acyl-chain is released from the membrane either sponta-
neously or after removal of the lipid portion by a PLD, such as
GPI-specific PLD (9).
CRYPTIC is another GPI-anchored, co-receptor for Nodal
that also plays a role in early embryonic development, specifi-
cally in the generation of the left–right axis (16). CRIPTO and
CRYPTIC are similar but expressed in different regions of
the embryo and basically play independent roles (16). CRIPTO
and CRYPTIC share 30% amino acid identity, have a similar
domain organization, and belong to the same protein family,
termed the EGF–Cripto-1/FRL1/Cryptic (CFC) family (17). In
contrast to CRIPTO, CRYPTIC is resistant to PGAP6 (9). This
indicates that PGAP6 differentiates the protein part of CRIPTO
from that of CRYPTIC and selectively attacks the GPI anchor
of CRIPTO but not CRYPTIC.
In this study, we aimed to understand the basis of the pro-
tein-selective action of PGAP6. We also aimed to determine
whether CRIPTO is the only substrate of PGAP6 among more
than 150 humanGPI-APs.
Results
CFC domain of CRIPTO determines sensitivity to PGAP6
Both CRIPTO and CRYPTIC consist of an N-terminal signal
sequence for translocation into the ER, an N-terminal (N)
*For correspondence: Taroh Kinoshita, tkinoshi@biken.osaka-u.ac.jp.
Present address for Gun-Hee Lee: Korea Zoonosis Research Institute, Jeon-
buk National University, Iksan, Jeonbuk, South Korea.
J. Biol. Chem. (2020) 295(42) 14501–14509 14501
© 2020 Lee et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.
ARTICLE
This is an Open Access article under the CC BY license.
domain, an EGF-like domain, a CFC domain, and a GPI-attach-
ment signal sequence (Fig. 1) (17). To understand the basis of
the different sensitivities of CRIPTO and CRYPTIC to PGAP6
and to gain insight into the substrate recognition of PGAP6, we
generated chimeric proteins between CRIPTO and CRYPTIC,
in which corresponding domains were swapped, and their sen-
sitivities to PGAP6 were tested. To achieve this, the chimeric
cDNAs were transfected into Chinese hamster ovary (CHO)
3B2A cells with either an empty vector or PGAP6 cDNA, and
the cell-surface levels of the chimeric proteins were determined
by flow cytometry (Fig. 1). If a chimera is sensitive to PGAP6,
one acyl-chain will be removed from the GPI anchor, and the
lipid moiety becomes lyso-PI. The resulting chimeric protein
with lyso-PI form of GPI anchor has only one acyl-chain for
membrane association and will be quickly released from the
cell surface like lyso-phospholipids (18, 19). Therefore, the cell-
surface level of the chimera will be reduced by co-transfection
with PGAP6. PGAP6 sensitivity was transferred to CRYPTIC
by the introduction of the CRIPTO CFC domain into CRYP-
TIC (chimera G; Fig. 1B). However, introduction of the N and
the EGF-like domains of CRIPTO into CRYPTIC did not con-
fer sensitivity to PGAP6 (chimeras B, C, and D). Conversely,
introduction of the CRYPTIC CFC domain into CRIPTO
reduced the sensitivity of CRIPTO to PGAP6 (chimera F).
Introduction of the N or the EGF-like domain of CRYPTIC
into CRIPTOmildly affected sensitivity to PGAP6 (chimeras A
and E). These results showed that the CFC domain confers sen-
sitivity to PGAP6 and suggests that PGAP6 recognizes the CFC
domain of CRIPTO for processing of its GPI anchor.
Site-directed CRIPTO mutants bearing amino acid substitu-
tions in the CFC domain were generated to further analyze the
basis of the CFC domain recognition by PGAP6 (Fig. 2). The
CFC domains of both CRIPTO and CRYPTIC consist of ;50
amino acids including six conserved cysteines that make three
disulfide bonds (Fig. 2A), suggesting that the CRIPTO and
CRYPTIC CFC domains have a similar compact structure (20).
Alanine mutations were introduced into residues of CRIPTO
that are not conserved in CRYPTIC (red in Fig. 2A). Mutant
CRIPTO proteins with mutations in the N-terminal region of
the CFC domain were expressed at normal levels (m1, m2, and
m4) or at mildly reduced levels (m3 and m5) (Fig. 2B) and dis-
played sensitivities to PGAP6 asWTCRIPTO (Fig. 2C).Mutant
Figure 1. CFC domain of CRIPTO determines sensitivity to PGAP6. A, schematics of domain organizations of CRYPTIC, CRIPTO, and their seven domain-
swapping chimeras (panels A–G). ss, signal sequence for ER localization; EGF, EGF-like domain; CFC, Cripto-1/FRL1/Cryptic domain; GPI ss, GPI attachment signal
sequence. Short peptides of 6 and 10 amino acids in CRYPTIC and CRIPTO, respectively, connect CFC and GPI ss. B, cell-surface levels of CRYPTIC, CRIPTO, and
their domain-swapping chimeras (panels A–G) on CHO cells with or without PGAP6 overexpression. PGAP6 sensitivity as determined by the percentage of
reduction of expression levels with PGAP6 overexpression is indicated on the right. WT CRIPTO and CRYPTIC were tested under stable transfection, whereas
chimeras were under transient transfection.
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CRIPTOs with mutations in the C-terminal region of the CFC
(m7–m9) had reduced expression levels (Fig. 2B) and lost sensi-
tivities to PGAP6 (Fig. 2C). The alanine mutations that reduced
expression of the mutant CRIPTO might have affected effi-
ciency of proper disulfide bond formation within the CFC do-
main. These results indicate that the C-terminal region of the
CFC domain is critical for recognition by PGAP6.
The N-terminal region of PGAP6 is critical for recognition of
CRIPTO
We next asked what part of PGAP6 is required for its activity
against CRIPTO. PGAP6 consists of the signal sequence for ER
translocation, a large N-terminal domain, an EGF domain, and
seven TM domains (Fig. 3A). To determine the critical region
for CRIPTO recognition, several truncation mutants of PGAP6
were generated and transfected into HEK293T cells expressing
HA-tagged CRIPTO. The cell-associated and the released HA-
tagged CRIPTO were assessed by Western blotting (Fig. 3B),
and the cell-surface levels of HA-tagged CRIPTO were exam-
ined by flow cytometry (Fig. 3C). WT PGAP6 reduced the cell-
surface levels of CRIPTO by 70% and increased the CRIPTO
released into the culture medium. The N domain–deleted
PGAP6 (DN) and the N domain and the EGF domain–deleted
PGAP6 (DNEN) lost almost all activity, whereas the EGF do-
main–deleted PGAP6 (DEGF) had mildly reduced activity (Fig.
3), indicating that the N domain of PGAP6 is critical for
activity.
PGAP6/TMEM8A, TMEM8B, and TMEM8C/myomaker
share a common domain organization and form the TMEM8
protein family. Amino acids with putative catalytic involvement
within the second and fifth TM domains are conserved in
PGAP6/TMEM8A and TMEM8B. TMEM8C/myomaker is
essential for myogenesis and hence termed myomaker (21).
Some of the putative catalytic amino acids are not conserved in
TMEM8C/myomaker, suggesting a nonenzymatic function.
We generated a chimera consisting of the N and EGF domains
of PGAP6 and the seven TM domains of TMEM8B (AnBc) to
test whether TMEM8B has GPI-specific PLA2 activity (Fig.
3A). AnBc had CRIPTO-releasing activity comparable with
PGAP6 (Fig. 3, B andC), supporting the concept that TMEM8B
may also be a GPI-specific PLA2. To determine whether the
N domain plus the EGF domain of TMEM8B have CRIPTO-
recognizing function, another chimera consisting of the N
and EGF domains of TMEM8B and the seven TM domains of
PGAP6 was generated (BnAc). BnAc was inactive in CRIPTO
Figure 2. PGAP6 sensitivities of CRIPTO mutants bearing amino acid substitutions within the CFC domain. A, comparison of amino acid sequences of
CFC domains of CRIPTO and CRYPTIC. *, conserved residues. Red letters, nonconserved residues substitutedwith alanines inmutants, m1–m9, indicated above.
Three intradomain disulfide bonds are shown below sequences. B, levels of WT and mutant (m1–m9) CRIPTO proteins with vector (V) or PGAP6 (P6) co-trans-
fection as assessed by Western blotting. Top panels, PGAP6;middle panels, tubulin; bottom panels, CRIPTO. C, levels of WT andmutant CRIPTO with PGAP6 co-
transfection as assessed by flow cytometry. Levels of CRIPTOwith vector co-transfectionwere taken as 100%.
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release (Fig. 3, B and C). The full-length TMEM8B was not
stably expressed after transfection into several mammalian
cell lines such as HEK293 and CHO, precluding further inves-
tigation of the substrate specificity of TMEM8B (data not
shown).
To demonstrate physical interaction between PGAP6 and
CRIPTO in the cells by a co-immunoprecipitation assay, an
enzyme-dead mutant of PGAP6, D610A, was prepared by sub-
stituting the putative catalytic aspartic acid 610 with alanine.
His-FLAG–tagged D610A PGAP6 (HF-PGAP6 D610A) was
co-transfected with HA-tagged CRIPTO, CRYPTIC, or CD25
into HeLaS3 cells. Co-immunoprecipitation of HF-PGAP6
D610Awith HA-tagged proteins was assessed byWestern blot-
ting against a rabbit anti-PGAP6 antibody. HF-PGAP6 D610A
co-immunoprecipitated with HA-tagged CRIPTO but not with
HA-tagged CRYPTIC and HA-tagged CD25 (Fig. 4), demon-
strating that PGAP6 and CRIPTO specifically interact with
each other in cells.
PGAP6 is not active toward a vast majority of GPI-APs, but
GPC3, prostasin, SPACA4, and contactin-1 are sensitive to
PGAP6
We next asked whether PGAP6 is active against other GPI-
APs because the activity of PGAP6 involves specific recognition
of a region of GPI-APs by the extracellular domain and the
PGAP6 extracellular domain is large. To examine the specific
recognition of PGAP6, the cDNAs of 79 human GPI-APs
were cloned, and an HA tag was introduced at their N termini
by replacing their ER translocation signal sequences with a
CD59 signal sequence fused with HA. After transfection into
HEK293 cells, the cell-surface expressions of 56 of 79 were
confirmed by flow cytometry using an anti-HA antibody.
PGAP6 sensitivity was assessed by percentage of reduction of
the cell-surface levels of HA staining by co-overexpression of
PGAP6. Of the 56 GPI-APs, only four other GPI-APs: GPC3,
SPACA4 (sperm acrosome-associated protein 4, also known
as SAMP14) (22), prostasin, and contactin-1, were sensitive
to PGAP6, showing .60% reduction (Table 1 and Fig. 5A for
SPACA4). Eight GPI-APs were mildly sensitive, showing 30%
to 60% reduction by PGAP6 overexpression, whereas 43
other GPI-APs were either not sensitive or only slightly sensi-
tive (Table 1). Therefore, PGAP6 has rather narrow specific-
ity against GPI-APs.
We then examined sperm/testis expression of mouse and
human PGAP6 because SPACA4/SAMP14 is expressed only in
testis and sperm. PGAP6 was detected in lysates of mouse
sperm and testis and human sperm byWestern blotting using a
rabbit polyclonal antibody raised against human PGAP6/
Figure 3. CRIPTO processing activities of truncation mutants of PGAP6 and chimeric proteins between PGAP6 and TMEM8B. A, schematic domain
organizations of PGAP6 mutants and the chimeras. B, cells expressing HA-CRIPTO were transfected with WT PGAP6 or its truncation mutants lacking the N
(DN), the EGF (DEGF), and the N plus the EGF (DNEN) domains, or chimeras of PGAP6 and TMEM8B. BnAc, N-terminal part of TMEM8B and C-terminal part of
PGAP6; AnBc, N-terminal part of PGAP6 and C-terminal part of TMEM8B. Cell lysates and anti-HA immunoprecipitates from culture media were analyzed by
Western blotting against anti-CRIPTO. Tubulin was used as a loading control. C, cell-surface levels of HA-CRIPTO after transfection of PGAP6, mutant PGAP6
and chimeras of PGAP6 and TMEM8B. Symbols of various PGAP6 constructs are the same as in B. Mean (long horizontal bars) and S.D. (short horizontal bars) of
n = 3 are shown. Vec, vector; IP, immunoprecipitation; IB, immunoblot.
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TMEM8A (Fig. 5B). By immunofluorescence staining with the
same antibody, PGAP6 was detected in the acrosomal cap (Fig.
5C). PGAP6 staining disappeared after the acrosomal reaction
as indicated by widened IZUMO1 staining (Fig. 5C). Therefore,
PGAP6 and SPACA4 are both expressed in the sperm head
before the acrosomal reaction. However, whether PGAP6-de-
pendent release of SPACA4 indeed occurs in sperm is yet to be
determined. Two other sperm GPI-APs, LY6K and TEX101,
which are substrates of another GPIase, tACE, were fully resist-
ant to PGAP6 (Table 1). It was reported that SPACA4 is resist-
ant to tACE (2, 3), further supporting that these GPIases are
selective to certain GPI-APs.
Finally, the sensitivity of free, unlinked GPI to PGAP6 was
examined. Some mouse tissues express free, unlinked GPI as
free glycolipids (23). Cultured cell lines, defective in GPI-trans-
amidase that attaches GPI to proteins, express high levels of
free GPI on their surface (23). Transfection of PGAP6 into
GPI-transamidase defective CHO cells reduced the level of free
GPI by 88% as assessed by staining with the free GPI-specific
T5 mAb (Fig. 6). These results suggest that PGAP6 accesses
GPI when the protein part does not exist and that the protein
parts of the vast majority of GPI-APs prohibit access of PGAP6
to the GPI moiety, whereas the protein parts of several GPI-
APs allow PGAP6 access.
Discussion
Because of their glycolipid membrane anchors, GPI-APs
can be potentially released from the cell surface by the actions
of GPIases. Previously characterized GPIases are selective to
only a few kinds of GPI-APs: GDE2 releases RECK and GPC6
(5,6), GDE3 releases uPAR and CNTFRa (7, 8), and tACE
releases TEX101 and LY6K (2, 3). We reported previously
that PGAP6 activity leads to the release of CRIPTO (9). Here,
we report that PGAP6 is also active toward only a small num-
ber of GPI-APs. Among the 56 GPI-APs tested under PGAP6
overexpression conditions, only CRIPTO, GPC3, SPACA4,
prostasin, and contactin-1 were highly sensitive to PGAP6.
All of these previously characterized GPIase-mediated
releases of select GPI-APs are the foundations of certain bio-
logical processes, such as neurogenesis, cell migration, sperm
maturation and embryonic development. PGAP6-dependent
release of GPC3, SPACA4, prostasin, and contactin-1 were
shown only under PGAP6 overexpression conditions. Further
studies are required to clarify whether the release of these
proteins occurs under physiological conditions and to iden-
tify possible biological processes that are associated with the
release of these proteins.
PGAP6 consists of a hydrophilic N-terminal extracellular
part and a hydrophobic C-terminal part with seven TM
domains. Our data showed that the extracellular part of
PGAP6 recognizes the protein part of substrate GPI-APs. For
CRIPTO, which has three distinct extracellular domains, the
C-terminal region of the CFC domain is recognized by
PGAP6. Because the extracellular part of PGAP6 is rather
large (.500 amino acids), it may recognize other substrate
GPI-APs. The hydrophobic C-terminal part of PGAP6 may
form a catalytic region for the PI moiety in GPI. The second
and the fifth TM domains contain putative catalytic amino
acid residues conserved in TMEM8B and other CREST family
members (11), such as PGAP3, a Golgi-resident GPI-APs-
specific phospholipase A2 involved in fatty acid remodeling
(24).
Figure 4. Physical association of PGAP6 and CRIPTO. An HF-tagged, enzyme dead PGAP6 mutant was co-transfected into HeLaS3 cells with HA-CRIPTO,
HA-CRYPTIC, and HA-CD25 as a negative control. Anti-HA immunoprecipitates were analyzed by Western blotting against PGAP6 to determine co-precipita-
tion (right panel). Expression levels of transfected proteins were assessed by Western blotting (left panel). GAPDH was used as a loading control. *, immature,
ER forms of CRIPTO and CRYPTIC. IP, immunoprecipitation; IB, immunoblot.
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We tested GPC1, GPC3, GPC4 and GPC5 for their sensitiv-
ities to overexpressed PGAP6. Only GPC3 was highly sensitive,
whereas GPC5 was weakly sensitive, and GPC1 and GPC4 were
essentially insensitive. GPC5 may not be sensitive to PGAP6
under physiological expression levels of PGAP6. GPC6 is
reported to be sensitive to GDE2. Therefore, at least two GPCs,
GPC3 and GPC6, are sensitive to GPI-cleaving/processing
phospholipases.
Experimental procedures
Antibodies, cells, and materials
T5_4E10 mAb (T5 mAb) against free GPI-GalNAc (mouse
IgM) was kindly provided by Dr. Jean François Dubremetz
(Montpellier University, Montpellier, France) (25). T5_4E10
mAb is available from BEI Resources, ATCC (catalog No. NR-
50267). Mouse anti-human PGAP6/TMEM8A mAb (clone
5C3, IgG2b) was a gift from Bio Legend Japan (Osaka, Japan).
Polyclonal rabbit anti-PGAP6 was raised by immunization with
a peptide corresponding to the C-terminal cytosolic tail of
mouse PGAP6 (Scrum). Monoclonal rabbit anti-CRIPTO
was from Cell Signaling Technology. Rat anti-mouse IZUMO1
mAb (clone KS64-125) was reported previously (2, 26). mAb anti-
GAPDH (clone 6c5, Thermo Fisher), anti–HA tag (H7),
anti-acetylated tubulin (clone 6-11B-1) (Sigma–Aldrich),
and anti-tubulin and anti-transferrin receptors (Zymed
Laboratories Inc., South San Francisco, CA, USA) were pur-
chased. Secondary antibodies used were horseradish peroxidase
Table 1
Sensitivities of human GPI-APs to PGAP6
No. GPI-AP Gene name Sensitivitya
1 CRIPTO TDGF1 High
2 Glypican 3 GPC3 High
3 Sperm acrosome-associated protein 4 SPACA4 High
4 Prostasin PRSS8 High
5 Contactin-1 CNTN1 High
6 Lymphocyte antigen 6D LY6D Medium
7 Ephrin A1 EFNA1 Medium
8 CD59 CD59 Medium
9 UL16-binding protein 1 ULBP1 Medium
10 Dipeptidase 2 DPEP2 Medium
11 CD55 CD55 Medium
12 CAMPATH-1 antigen CD52 Medium
13 Ephrin A3 EFNA3 Medium
14 Ly6/PLAUR domain–containing protein 2 LYPD2 Low
15 Lymphocyte antigen 6E LY6E Low
16 Carboxypeptidase M CPM Low
17 Glial cell line–derived neurotrophic factor family receptor a-1 GFRA1 Low
18 Glypican 5 GPC5 Low
19 Ecto-ADP-ribosyltransferase 3 ART3 Low
20 Prion protein PRNP Resistant
21 Opioid-binding protein/cell adhesion molecule OPCML Resistant
22 Cilliary neurotrophic factor receptor subunit a CNTFR Resistant
23 Reversion-inducing cysteine-rich protein with Kazal motifs RECK Resistant
24 Alkaline phosphatase, non–tissue-specific isozyme ALPL Resistant
25 Alkaline phosphatase, germ cell type ALPG Resistant
26 Monocyte differentiation antigen CD14 CD14 Resistant
27 Signal transducer CD24 CD24 Resistant
28 CD48 antigen CD48 Resistant
29 Carbonic anhydrase 4 CA4 Resistant
30 Carboxypeptidase O CPO Resistant
31 CRYPTIC CFC1 Resistant
32 Ecto-ADP-ribosyltransferase 4 ART4 Resistant
33 Ectonucleotide pyrophosphatase family member 6 ENPP6 Resistant
34 Folate receptor a FOLR1 Resistant
35 Glypican 1 GPC1 Resistant
36 Glypican 4 GPC4 Resistant
37 Lymphocyte antigen 6K LY6K Resistant
38 Lymphocyte antigen 6 complex G6C LY6G6C Resistant
39 Lymphocyte antigen 6 complex G6D LY6G6D Resistant
40 Ly6/PLAUR domain–containing protein 1 LYPD1 Resistant
41 Ly6/PLAUR domain–containing protein 6B LYPD6B Resistant
42 Netrin G1 NTNG1 Resistant
43 Neural cell adhesion molecule 1 NCAM1 Resistant
44 Neuronal growth regulator 1 NEGR1 Resistant
45 Neuritin NRN1 Resistant
46 Neuritin-like protein NRN1L Resistant
47 Oligodendrocyte-myelin glycoprotein OMG Resistant
48 Pantetheinase VNN1 Resistant
49 Prion-like Doppel PRND Resistant
50 Prostate stem cell antigen PSCA Resistant
51 Testis-expressed protein 101 TEX101 Resistant
52 Thy-1 THY1 Resistant
53 Tumor necrosis factor receptor superfamily 10C TNFRSF10C Resistant
54 UL16-binding protein 2 ULBP2 Resistant
55 Urokinase plasminogen activator surface receptor PLAUR Resistant
56 59-Nucleotidase NT5E Resistant
aPercentage of reduction by PGAP6: high,.60%; medium, 30–60%; low, 10–30%; resistant,,10%.
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(HRP)–conjugated anti-mouse IgG (GE Healthcare) and anti-
rabbit IgG (Cell Signaling Technology), phycoerythrin-conju-
gated goat anti-mouse IgG (BD Biosciences and PharMingen,
San Diego, CA), Alexa 488–conjugated goat anti-mouse IgM,
Alexa 488–conjugated goat anti-mouse IgG and goat anti-rabbit
IgG, and Alexa 594–conjugated goat anti-rabbit IgG (Life
Technologies).
HEK293T cells stably expressing HA-tagged CRIPTO were
established by transfection of linearized pME-pgkpuro-HA-
CR1 and cultured in Dulbecco’s modified Eagle’s medium
containing 10% fetal calf serum and 10 mg/ml puromycin as
described before (9). To prepare pME-pgkpuro-HA-CR1, we
obtained human CRIPTO cDNA (Kazusa DNA Research
Institute, Kisarazu, Japan) and cloned it into a mammalian
expression plasmid pME bearing puromycin resistance gene
and a segment of signal sequence plus HA tag. CHO cells
used in this study were CHO 3B2A cells derived from CHO-
K1 cells (ATCC) and stably express two human GPI-APs:
CD59 and DAF (27). All CHO cell lines including WT 3B2A
and 3B2A cells stably expressing HA-PGAP6, His-FLAG-
PGAP6, PGAP6-FLAG, or HA-CRYPTIC (human CRYPTIC
HA-tagged at the N terminus after the ER signal sequence) were
cultured in Ham’s F-12 medium containing 10% fetal calf serum
with 6 mg/ml blasticidin, 10 mg/ml puromycin, or 500 mg/ml
hygromycin, if necessary. Human CRYPTIC cDNA (clone
AK315326) was obtained from NITE Biological Resource Center
(Kisarazu, Japan). HeLa S3 cells (ATCC) were stably transfected
with HA-CRIPTO, HA-CRYPTIC, and HA-CD25. They were
then transiently transfected with an empty pME or pME bearing
His-FLAG–tagged PGAP6 with D610A mutation (HF-PGAP6
D610A).
Plasmids of human GPI-APs’ cDNAs were obtained from
Invitrogen. Their protein coding regions lacking the N-ter-
minal signal sequences were cloned into pME expression
vector bearing an N-terminal signal sequence of CD59
plus HA tag so that N-terminally HA-tagged GPI-APs are
expressed.
Mouse and human samples
Mouse testis and sperm were obtained from 10-week-old
B6D2F1 mice. Animal experiments were approved by the
Animal Care and Use Committee of the Research Institute
for Microbial Diseases, Osaka University, Japan. Human
sperm were obtained from a volunteer after consent. Experi-
ments using human samples were approved by the Ethics
Committee of the Research Institute for Microbial Diseases,
Osaka University, Osaka, Japan, and abide by the Declara-
tion of Helsinki principles. Lysates of sperm and testis were
prepared in a lysis buffer (6 M urea, 2 M thiourea, and 2% so-
dium deoxycholate). PGAP6 and acetylated tubulin as a
loading control were detected by Western blotting against
rabbit polyclonal antibody to human PGAP6 and anti-tubu-
lin antibody. PGAP6 and IZUMO1 in mouse sperm were
detected by immunofluorescence staining by rabbit polyclo-
nal antibody to human PGAP6 (1 in 50 dilution) and rat
mAb to mouse IZUMO1 (1 in 500 dilution) after incubation
of sperm in TYHmedium (28) for 2 h.
Flow cytometry
The cells were incubated with mouse T5 mAb (1 in 1,000
dilution of ascites) or anti-HA in FACS buffer (PBS containing
Figure 5. PGAP6 sensitivity of SPACA4 and expression of PGAP6 in testis and sperm. A, sensitivity of SPACA4 to PGAP6. HEK293 cells expressing
HA-SPACA4 were co-transfected with vector (top panel) or PGAP6 (bottom panel). Mean fluorescence intensities of anti-HA staining are shown in the
panels. Background fluorescence intensity was 36. B, Western blotting determination of PGAP6 in mouse testis and mouse and human sperm. The tes-
tis PGAP6 appeared twice as big as the sperm PGAP6. C, immunofluorescence staining of mouse sperm for PGAP6. PGAP6 was present in the acroso-
mal cap and disappeared after the acrosomal reaction. *, acrosome reacted sperm indicated by wider IZUMO1 staining. Scale bars, 10 mm. DIC,
differential interference contrast.
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1% BSA and 0.1% NaN3) on ice for 25 min. The cells were then
washed twice in FACS buffer followed by staining with Alexa
Fluor 488–conjugated goat anti-mouse IgM for T5 mAb and
phycoerythrin-conjugated goat anti-mouse IgG for anti-HA in
FACS buffer. After washing twice with FACS buffer, the cells
were analyzed by the BD FACSCanto II.
Western blotting
The samples were run on 10–20% gradient SDS-PAGE gels
followed by transfer to polyvinylidene difluoride membranes.
The polyvinylidene difluoride membranes were blocked with
5% nonfat milk in TBS/Tween 20 at room temperature for 1 h.
PGAP6, HA-tagged proteins, tubulin, and GAPDH were
detected using rabbit anti-PGAP6, and mouse anti-HA, anti-
tubulin and anti-GAPDH (1:4000) followed by detection with
HRP-conjugated anti-rabbit IgG and HRP-conjugated anti-
mouse IgG (1:4000).
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